News und Analysen

Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, more than doubled recently. The market started hurling money at the stock after some mid-stage clinical trial results

Image source: The Motley Fool.

Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA)

The arrival of a potential new rival in an important product category dinged the share prices of pharmaceutical companies Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) on Tuesday. Both slumped

With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last

With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last

Many investors have seen Novavax (NASDAQ: NVAX) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could

Gene-sequencing stock Illumina (NASDAQ: ILMN) was a standout in the biotech sector Monday, with its share-price rise convincingly beating the S&P 500 index. Investors were cheered by a stock buy

Gene-sequencing stock Illumina (NASDAQ: ILMN) was a standout in the biotech sector Monday, with its share-price rise convincingly beating the S&P 500 index. Investors were cheered by a stock buy

Gene-sequencing stock Illumina (NASDAQ: ILMN) was a standout in the biotech sector Monday, with its share-price rise convincingly beating the S&P 500 index. Investors were cheered by a stock buy

Particular financial metrics have been proven to indicate market-beating potential when analyzing stocks. Three examples are businesses with consistently growing dividend payments and a low payout

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely

Abbott Laboratories (NYSE: ABT) has proven itself as a long-term winner for investors. The healthcare giant has grown earnings over time, and the shares have climbed too. In just the past year

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing

For seasoned healthcare investors, Medtronic (NYSE: MDT) needs no introduction. The medical device specialist has been around for decades, successfully navigating one of the most highly regulated

There are well over 5,000 stocks on the market that pay dividends. It would take you years to analyze each one of them in detail. Fortunately, you don't have to exert such an effort.

Three Fool.com

Eli Lilly (NYSE: LLY) has been on a tear this past year, rising up to become the most valuable healthcare stock in the world. It soared past UnitedHealth Group and other top healthcare companies in